Evaluation of the effect of silymarin on hepatotoxicity induced by Remdesivir

Evaluation of the effect of Silymarin on hepatotoxicity induced by Remdesivir in patients with COVID-19 admitted to Shahrekord hospitals

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201227049854N1

Enrollment

Registered

2021-07-11

Start date

2021-02-19

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Remdesivir + Livergel 140 mg 3 times a day for 1 week. Intervention 2: Control group: Remdesivir + placebo 3 times a day for 1 week.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with positive covid19 PCR test who have been treated with Remdesivir Spo2<93% Patient with lung infiltration Absence of underlying liver disease Liver enzymes less than 5 times normal

Exclusion criteria

Exclusion criteria: Increased liver enzymes more than 5 times normal Patient dissatisfaction Pregnant or lactating patients Patients with glomerular filtration less than 50 mg / min

Design outcomes

Primary

Measure	Time frame
Direct Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Total Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Aspartate Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alanine Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alkaline Phosphatase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.	—

Measure

Time frame

Direct Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Total Billirubin. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Aspartate Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alanine Aminotransferase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.;Alkaline Phosphatase. Timepoint: Measurement of liver enzymes on the first and seventh days of the study. Method of measurement: Measurement of liver enzymes by BT 3500 device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Habibi

Shahre-kord University of Medical Sciences

Hajar-Hospital@skums.ac.ir+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026